Skip to main content
padlock icon - secure page this page is secure


Buy Article:

$42.00 + tax (Refund Policy)

The effect of chemotherapeutic and/or immunotherapeutic drugs on cells obtained from primarily cultured renal cell carcinoma (RCC) was investigated in a microcalorimetric study. This method enables the detection of heat flow in the submicrowatt range, which corresponds to a 1.0x10(-6) degrees C temperature change. The thermal power of 10 individual cell lines from patients with advanced RCC was measured by incubating cells with or without anti-cancer drugs (5-fluorouracil, interferon-alpha-2a, interleukin-2). Using a 4-channel microcalorimeter, it could be shown, that the combination of 5-FU with IFN-alpha-2a or IFN-alpha-2a plus IL-2 led to a significant reduction in thermal cell activity, compared with the addition of 5-FU on its own. These microcalorimetric observations appear to reflect the anti-neoplastic properties of the drugs tested in this study when compared with the findings in a calorimetric assay (MTT-assay).
No Reference information available - sign in for access.
No Citation information available - sign in for access.
No Supplementary Data.
No Article Media
No Metrics

Document Type: Research Article


Publication date: April 1, 1995

More about this publication?
  • The International Journal of Oncology provides an international forum for the publication of the latest, cutting-edge research in the broad area of oncology and cancer treatment. The journal accepts original high quality works and reviews on all aspects of oncology research including carcinogenesis, metastasis, epidemiology, chemotherapy and viral oncology. Through fair and efficient peer review, the journal is dedicated to publishing top tier research in the field, offering authors rapid publication as well as high standards of copy-editing and production. The International Journal of Oncology is published on a monthly basis in both print and early online.
  • Editorial Board
  • Information for Authors
  • Submit a Paper
  • Subscribe to this Title
  • Information for Advertisers
  • Terms & Conditions
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more